Vemurafenib in the French temporary authorization for use metastatic melanoma cohort: a single-centre trial.
2014
Vemurafenib, a selective BRAF inhibitor, has recently shown an improved overall survival (OS) in metastatic melanoma with V600E mutation in phase 2 and 3 trials. Patients with BRAF V600E metastatic melanoma received vemurafenib orally, in the French temporary authorization for use program from April
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
9
References
14
Citations
NaN
KQI